What is ipamorelin?
Ipamorelin mimics ghrelin at the growth hormone secretagogue receptor — a selective nudge that asks the pituitary for a growth-hormone pulse without meaningfully raising cortisol or appetite. That selectivity is why it's so often studied in combination with CJC-1295 or tesamorelin.
These articles explain the mechanism, the combinations, and the evidence in plain language. Like everything Promise offers, it's prescription-only, and a licensed provider makes the call. If you're weighing it against sermorelin or tesamorelin, the comparison articles are the place to start.
4 articles on this topic
-
Sermorelin vs CJC-1295: What Actually Differs
Both signal the pituitary through the GHRH pathway. The practical difference is duration: sermorelin is brief, while DAC-bearing CJC-1295 was engineered to remain active far longer.
-
CJC 1295 Ipamorelin Dosage: What Studies Used
There is no validated combined dose. Human studies used different formulations, routes and objectives, so a prescriber has to identify the exact product, interpret the clinical context and set the schedule.
-
Ipamorelin Benefits, Side Effects, Legal Status
Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.
-
CJC-1295 and Ipamorelin: Why They're Paired
One prescription, two receptors: CJC-1295 signals through the GHRH receptor while ipamorelin mimics ghrelin at GHSR-1a — two separate inputs to the same growth-hormone axis.